|Dr. Ting Xu Ph.D.||Founder, Exec. Chairman & CEO||N/A||N/A||1973|
|Mr. Weihao Xu||Chief Financial Officer||N/A||N/A||1983|
|Ms. Yang Liu||VP of Corp. Operations & Exec. Director||N/A||N/A||1972|
|Ms. Jin'nan Wang||Director of Investor Relations & Joint Company Sec.||N/A||N/A||1982|
|Mr. Yumin Wan||VP of Gov. Affairs & PR||N/A||N/A||1972|
|Dr. Mike Liu M.B.A., Ph.D.||Sr. VP of Bus. Devel.||N/A||N/A||1966|
|Dr. Johannes Nippgen||Chief Medical Officer||N/A||N/A||1968|
|Mr. Jing Han||Chief Commercial Officer||N/A||N/A||N/A|
|Ms. Lok Yee Chan A.C.I.S., A.C.S.||Joint Company Sec.||N/A||N/A||1991|
Alphamab Oncology, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial with potential broad applications in both auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that has completed phase II pivotal clinical trials for deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III pivotal trials for biliary tract cancer. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
Alphamab Oncology’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.